Q5147Inj, aflibercept-ayyh, 1 mg

Published CMS Medicare Part B payment-limit context for Q5147, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.

CMS payment limit

$803.255

per 1 MG · Medicare Part B

Down 2.2%from $821.396 in 2026-Q2

Current quarter: 2026-Q3FinalEffective July 1, 2026
Billing unit: 1 MG

Payment limit over time

$879.3352$785.6098

2024-Q4: Not published; 2025-Q1: Not published; 2025-Q2: $795.861; 2025-Q3: $869.084; 2025-Q4: $859.363; 2026-Q1: $866.203; 2026-Q2: $821.396; 2026-Q3: $803.255

No current FDA shortage matchThe latest completed FDA data has no affected record matching the Aflibercept ingredient family (FDA data as of August 20, 2026).

Email me when FDA shortage status changes

Pavblu

Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.

Other Aflibercept presentations

3 other CMS codes

Source-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.

Swipe to see all columns

HCPCS	CMS description	Current quarter 2026-Q3	Prior quarter 2026-Q2	Change
J0177	Inj, aflibercept hd, 1 mg	$298.683 per 1 MG	$301.177 per 1 MG	Down 0.8%
J0178	Aflibercept injection	$743.605 per 1 MG	$731.885 per 1 MG	Up 1.6%
J9400	Inj, ziv-aflibercept, 1mg	$8.674 per 1 MG	$8.608 per 1 MG	Up 0.8%

Email me when a new presentation appears

Put another code on your radar.

Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.

Explore CMS codes